Dermatomyositis Leukopak
About: LeukoCore Dermatomyositis Leukopak contains concentrated immune cells from donors with clinically confirmed Dermatomyositis, collected via apheresis.
High-Yield LeukoCore Dermatomyositis Leukopaks for Immunology Research
LeukoCore Dermatomyositis Leukopak biospecimens are collected from donors clinically diagnosed with Dermatomyositis through IRB-approved apheresis procedures. Each leukopak contains large quantities of peripheral blood mononuclear cells (PBMCs), making it ideal for immune profiling, cytokine analysis, and studying immune cell interactions involved in muscle and skin inflammation.
Product Features
- Research Use Only (RUO) human leukopaks
- Clinically confirmed Dermatomyositis donors
- High cell yield for large-scale studies
- Processed and shipped within 24 hours of collection
- Fresh or cryopreserved options available
- IRB-approved and ethically sourced
- Infectious disease testing
- HLA-A typing
De-identified Donor Data
- Verified Dermatomyositis diagnosis from healthcare providers
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported medication history and allergies
- Relevant clinical data
Applications
- Immune cell characterization in Dermatomyositis
- Therapeutic development and screening
- Cell-based assays and cytokine profiling
- Multi-omics studies including single-cell sequencing
Compliance and Quality Assurance
- Collected under IRB oversight with donor e-consent (21 CFR Part 11 compliant)
- HIPAA-compliant handling of donor information
- Rigorous donor screening and documentation
Ordering & Customization
Dermatomyositis Leukopak is available fresh or cryopreserved. For international shipping or regulatory documentation, please contact learnmore@sanguinebio.com.
Protocols & Documentation
-
Download
Leukopak Cryopreservation
Standard operating procedure for cryopreserving leukopak units with controlled freezing and post-thaw viability targets.
-
Download
Leukopak Thawing
Validated thawing workflow for cryopreserved leukopaks to maximize recovery while maintaining sterility and chain of custody.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Leukopak
Frequently Asked Questions
1 Answer
All our samples have self-reported infectious disease testing and verified clinical diagnosis. Many of our samples have the option of electronic medical records provided and our prospective collection offers the opportunity for patient reported outcomes and surveys. Learn more here. https://sanguinebio.com/patient-reported-outcomes-pro-surveys-questionnaires/
1 Answer
YES – Certificate of analysis is available upon request.
1 Answer
Lead times vary from ready to ship inventory to prospective studies.
1 Answer
International shipping is available. We also work with a number of distributors. Contact us to discuss options at learnmore@sanguinebio.com.
1 Answer
We have several ordering methods. You can order directly online with a PO or credit card or contact us to have a sales specialist help with your order. https://sanguinebio.com/request-quote/
1 Answer
You can request a quote on this page or contact us at learnmore@sanguinebio.com. https://sanguinebio.com/request-quote/
1 Answer
NO – no minimum order requirements.
1 Answer
For bulk pricing inquiries, please contact: LearnMore@sanguinebio.com
1 Answer
YES – Unique donors can be specified.
1 Answer
International shipping is available. For more information and documentation requirements, please contact learnmore@sanguinebio.com.
1 Answer
YES – We offer cryopreservation of leukopaks and PBMC processing, aliquoting, and cryopreservation.
1 Answer
YES – We offer full and half size leukopaks both fresh and cryopreserved.
Ask a Question
Need a custom Leukopak cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.